Gardasil (HPV Vaccine) Lawsuit
POTS & Autoimmune Claims
Individual product liability claims alleging POTS and autoimmune injuries from HPV vaccination. Important: The overwhelming scientific consensus supports Gardasil's safety. This litigation represents claims by individual plaintiffs, not regulatory findings of unsafety.
Key Takeaways
- 129 pending cases of 258 total filed — ~50% resolution rate
- 16 bellwether cases selected (June 2023) for POTS and POI/POF claims only
- Overwhelming scientific consensus: CDC, FDA, WHO, EMA all confirm Gardasil is safe and effective
- 270+ million doses distributed globally; no causal link to POTS/POI/POF found in large-scale studies
- Bruesewitz v. Wyeth (2011) preempts all design-defect vaccine claims; VICP must be filed first
Scientific Consensus on Gardasil Safety
The overwhelming scientific consensus supports Gardasil safety. The CDC, FDA, European Medicines Agency (EMA), and World Health Organization (WHO) have all reviewed extensive clinical and post-approval data and found no causal link between HPV vaccination and POTS, POI/POF, or other autoimmune conditions.
Over 270 million doses have been distributed worldwide since 2006. Large-scale safety studies from multiple countries (Denmark, Sweden, United States, France) involving millions of vaccinated women found no increased risk of the alleged conditions.
This MDL represents individual claims by plaintiffs. The existence of litigation does not indicate product unsafety. Individual lawsuits and regulatory safety determinations are separate legal matters.
May 2026 Updates Latest
129 pending actions out of 129 total per the May 2026 JPML statistics report — the federal MDL caseload before Judge Bell in the Western District of North Carolina has held flat, even as more than 15,000 plaintiffs are now pursuing related Gardasil injury claims across federal MDL, state court, and Vaccine Court forums combined, making this one of the largest pharmaceutical MDLs currently active.
The litigation has entered its defining phase, with expert admissibility rulings and bellwether trials expected to drive the trajectory through mid-2026 — outcomes likely to determine whether the litigation accelerates toward global settlement discussions. The Fourth Circuit's September 4, 2025 published opinion affirming dismissal of three bellwether cases on Vaccine Act timeliness grounds (failure to file within the three-year onset-of-symptom window) continues to shape strategy, with more claimants now filing Vaccine Court petitions first before pursuing civil litigation against Merck on manufacturing-defect and fraud theories that sidestep preemption.
Key Facts (May 2026)
| Pending Actions | 129 cases in federal MDL |
| Total Actions Filed | 258 cases |
| Resolution Rate | ~50% of filed cases resolved/dismissed |
| Key Defendant | Merck & Co., Inc. |
| Presiding Judge | Hon. Kenneth D. Bell (W.D. North Carolina) |
| MDL Created | August 4, 2022 |
| Bellwether Cases Selected | 16 cases (June 2023): POTS and POI/POF only |
| Alleged Injuries | POTS, POI/POF, autoimmune conditions |
| Scientific Consensus | CDC, FDA, WHO: Vaccine safe and effective |
Case Trajectory
Gardasil MDL filings grew steadily to 224 pending cases by September 2025 before the March 2025 bellwether dismissals and Fourth Circuit appeal reduced new filings. Currently 129 cases remain pending.
Source: JPML MDL Statistics Reports, August 2022–May 2026
1 What Is This Lawsuit About?
MDL-3036 is a multidistrict litigation in the Western District of North Carolina containing individual product liability claims against Merck & Co. by plaintiffs who allege they suffered injuries from Gardasil or Gardasil 9 HPV vaccines.
Plaintiffs primarily allege two conditions:
- 1. POTS (Postural Orthostatic Tachycardia Syndrome) — a cardiovascular condition where heart rate increases excessively upon standing, causing dizziness, fatigue, and fainting
- 2. POI/POF (Primary Ovarian Insufficiency/Failure) — early-stage ovarian dysfunction in women of reproductive age
Some plaintiffs also allege other autoimmune conditions such as lupus, Hashimoto's thyroiditis, and chronic fatigue syndrome.
2 HPV & the Need for Vaccination
Human papillomavirus (HPV) is the most common sexually transmitted infection. According to the CDC, nearly 80% of sexually active people will contract HPV at some point in their lives. While most infections clear naturally, persistent infection with high-risk HPV types causes cancer.
Global Cancer Burden:
HPV vaccine impact: In countries with high HPV vaccination rates, cervical cancer rates have declined by 40-90% in vaccinated cohorts. This represents one of the most significant public health achievements in cancer prevention in recent decades.
The HPV vaccines prevent infection with the high-risk types responsible for most cancers. Gardasil prevents 2 types (16, 18) responsible for ~70% of cervical cancers. Gardasil 9 prevents 9 types responsible for ~90% of cervical cancers.
3 Gardasil Development & Approval
Gardasil (quadrivalent) was developed by Merck and approved by the FDA on June 8, 2006. Before approval, it underwent extensive clinical testing in over 15,000 clinical trial participants across multiple countries and multiple phases of testing.
Gardasil (2006)
- • 4-valent vaccine
- • Types 6, 11, 16, 18
- • FDA approved June 2006
- • Now discontinued in US
Gardasil 9 (2014)
- • 9-valent vaccine
- • Types 6, 11, 16, 18, 31, 33, 45, 52, 58
- • FDA approved December 2014
- • Current standard of care
The vaccine is given as a series of 2-3 injections depending on age at first dose. Age recommendations have expanded from initial 9-12-year-old approval to now include catch-up vaccination through age 26 for all genders.
Cervarix (by GlaxoSmithKline) is a competing 2-valent HPV vaccine also available and effective against HPV types 16 and 18.
4 Safety Profile & Large-Scale Monitoring
CRITICAL: Large-scale post-approval safety studies have consistently found Gardasil to be safe. Multiple countries have conducted massive prospective and population-based studies involving millions of vaccinated girls with follow-up spanning over a decade.
Common Side Effects (injection site and immediate):
- Pain, redness, swelling at injection site
- Headache
- Fever
- Syncope (fainting) — often related to injection anxiety
LARGE-SCALE SAFETY STUDIES:
Denmark-Sweden Cohort Study
Hviid et al. (2017), New England Journal of Medicine
Population: 1 million Danish and Swedish girls, ages 10-30, vaccinated 2006-2013
Conclusion: No evidence that HPV vaccination increased risk of autoimmune diseases.
US Vaccine Safety Datalink (VSD) Study
CDC VSD Network surveillance database
Population: 840,000+ doses administered, followed prospectively
Ongoing monitoring: CDC conducts continuous safety surveillance through VSD and CISA networks. No POTS signal identified.
French EVACAR Study
Autoimmune disease surveillance in vaccinated populations
Population: 2+ million French girls tracked 2006-2019
5 Plaintiffs' Allegations & Scientific Response
Plaintiffs in this MDL allege that Gardasil caused POTS, POI/POF, and autoimmune conditions. Their theories include:
Plaintiff Theories
- • Aluminum adjuvant triggers systemic autoimmune response
- • Molecular mimicry between vaccine and body's own proteins
- • Systemic immune activation causes autonomic dysfunction (POTS)
- • Ovarian tissue cross-reactivity causes POI/POF
Scientific Response:
1. Temporal Coincidence, Not Causation
POTS and POI/POF typically emerge in women aged 15-30 — the exact age when HPV vaccination occurs. This creates temporal coincidence: the conditions would appear at the same time vaccination occurs by pure chance. Large-scale studies controlling for age and population rates show vaccination does not increase the background incidence of these conditions.
2. "Unmasking" Effect Explanation
Some argue vaccine-induced immune activation might "unmask" latent autoimmune disease. However, large cohort studies comparing vaccinated and unvaccinated girls of the same age find identical rates of autoimmune disease onset. If unmasking occurred, vaccinated groups would show higher rates.
3. Aluminum Adjuvant Safety
HPV vaccines contain ≤0.125 mg aluminum per dose — a dose far below exposures in routine childhood vaccines (many contain 0.5-1.2 mg). Dietary aluminum intake is typically 10-100 mg/day. Large-scale studies have found no link between vaccine aluminum and autoimmune disease.
6 VICP & Bruesewitz Preemption
Vaccine Injury Compensation Program (VICP) is a no-fault system created by Congress in 1986 under the National Childhood Vaccine Injury Act. Before filing a lawsuit against a vaccine manufacturer, plaintiffs must file a claim with the VICP first.
VICP: The Federal Program
- • No-fault compensation program
- • Funded by vaccine excise tax
- • No need to prove manufacturer negligence
- • Claims decided by VICP judges
- • Can file simultaneously with court case
240-Day Withdrawal Rule
- • Must file VICP first
- • Can withdraw if dissatisfied
- • Have 240 days to decide
- • Then can proceed to civil court
- • Filing VICP stops statute of limitations
VICP Data on HPV Vaccine:
Important: VICP has NOT added POTS or POI/POF to the Vaccine Injury Table (the list of conditions presumed to be vaccine-caused). This means VICP petitioners must prove causation by preponderance of evidence, and very few such cases have succeeded.
Bruesewitz v. Wyeth (2011):
In Bruesewitz v. Wyeth, 562 U.S. 223 (2011), the Supreme Court held that design-defect claims against vaccine manufacturers are preempted by federal law. This means plaintiffs cannot sue vaccines for being defectively designed — they can only sue for failure to warn or manufacturing defects.
This is a significant legal barrier in the Gardasil MDL. Many plaintiff allegations focus on the vaccine's inherent design (e.g., "the vaccine's immune activation causes POTS"). Such design-defect claims are preempted, leaving only failure-to-warn theories available.
7 MDL History & Current Litigation Status
JPML transfers HPV vaccine cases to W.D. North Carolina on August 4, 2022. Judge Kenneth D. Bell assigned.
Court selects 16 bellwether cases for trial management. Selection limited to POTS and POI/POF claims only. Other autoimmune claims remain in regular MDL queue.
Court conducts Daubert hearings on general causation. Plaintiffs attempt to establish that Gardasil can cause POTS and POI/POF. Expert testimony and scientific evidence presented.
Court appears to have granted summary judgment for Merck in bellwether POTS cases. Opinion: 770 F. Supp. 3d 893. POI/POF bellwether status ongoing.
MDL remains active with 129 pending cases of 258 total. Approximately 50% of filed cases have been resolved or dismissed. Small docket relative to other pharmaceutical MDLs.
8 Settlement Status & Litigation Outlook
No global settlement has been announced or negotiated. This is a critical distinction from some other pharmaceutical MDLs where manufacturer settlement agreements resolve thousands of cases at once.
Current Status:
- • Small docket: 258 total cases is small compared to major pharmaceutical MDLs (Depo-Provera has 3,099+ cases; Ozempic has 1,700+)
- • Defense prevailing: Summary judgment appears granted for Merck in bellwether POTS cases; limited plaintiff success in early litigation phases
- • Limited settlement activity: High resolution rate (50%) likely reflects non-compliance dismissals and Daubert/SJ wins for defense, not generous settlement offers
- • Scientific headwinds: Large-scale safety studies, CDC/FDA positions, and Bruesewitz preemption all favor defendant Merck
Settlement Prospect Assessment
Settlement prospects appear limited. Global settlement would require Merck to agree to pay substantial compensation despite favorable case law (Bruesewitz), lack of scientific evidence of causation, and apparent early trial wins. Without a significant shift in litigation dynamics or unexpected trial verdict, a global settlement is unlikely. Individual settlements may occur, but only for cases with strong specific causation evidence — a high bar given the scientific consensus.
Frequently Asked Questions
Is Gardasil safe? What do health agencies say?
Yes. Overwhelming scientific consensus supports Gardasil's safety. The CDC, FDA, European Medicines Agency, and WHO have all reviewed extensive clinical and post-approval safety data from millions of doses and found no causal link between Gardasil and POTS, POI/POF, or autoimmune diseases. The WHO declared HPV vaccines "extremely safe" in 2017 after reviewing safety data on over 200 million doses globally.
If Gardasil is safe, why do these lawsuits exist?
POTS and POI/POF occur naturally in millions of unvaccinated women at the same life stages when vaccination happens. Individual lawsuits arise when plaintiffs attribute their condition to the vaccine based on temporal coincidence (it happened after vaccination). However, regulatory safety determinations, large epidemiological studies, and scientific consensus are separate from whether individuals file lawsuits. Litigation exists; scientific evidence of causation does not.
What is POTS and POI/POF? Do they occur in unvaccinated women?
POTS (Postural Orthostatic Tachycardia Syndrome) is a cardiovascular disorder causing excessive heart rate increase upon standing. POI/POF (Primary Ovarian Insufficiency/Failure) is early ovarian dysfunction. Both occur in millions of women who have never received Gardasil. Background incidence in unvaccinated populations is comparable to vaccinated populations — a key finding from large cohort studies.
Must I file a VICP claim before suing?
Yes, absolutely. Under the National Childhood Vaccine Injury Act (42 U.S.C. §300aa-11), you must file a claim with the Vaccine Injury Compensation Program (VICP) first. You have 240 days to decide if you want to proceed to federal court. Filing the VICP claim also stops the statute of limitations for civil litigation, giving you time to evaluate both options. Many cases are filed in both venues simultaneously.
What is the Bruesewitz preemption? How does it affect my case?
Bruesewitz v. Wyeth (2011) is a Supreme Court decision holding that design-defect claims against vaccine manufacturers are preempted by federal law. This means you cannot sue that the vaccine's design itself is defective. You can only pursue failure-to-warn or manufacturing defect claims. Many plaintiff theories (e.g., "the vaccine's immune activation is inherently defective") are preempted. This is a significant legal barrier in the Gardasil MDL.
What are settlement prospects in this MDL?
Limited. No global settlement has been announced. The MDL remains small (258 cases) with defense apparently prevailing in early litigation phases. Merck faces favorable case law (Bruesewitz), lack of scientific evidence of causation, and likely views settlement as economically irrational. Individual settlements may occur for cases with strong specific evidence, but widespread settlement appears unlikely without a major shift in litigation or trial outcomes.
Should I still get the HPV vaccine? Consult my doctor?
Consult your doctor or healthcare provider. The CDC, FDA, and major medical organizations recommend HPV vaccination for cancer prevention. Gardasil 9 prevents ~90% of cervical, anal, oropharyngeal, and other HPV-related cancers. Individual health considerations should be discussed with your healthcare provider. The existence of litigation does not indicate product unsafety — large population studies consistently find benefits outweigh minimal risks for the general population.
Can I still file a case if the MDL is active?
Potentially, yes. The MDL is active and accepting new cases. However, you must first file a VICP claim and allow 240 days to assess your case. Statute of limitations varies by state (typically 2-4 years from injury discovery). If you believe you have a Gardasil injury claim, contact an attorney experienced in vaccine litigation to discuss VICP filing and potential MDL inclusion.
Sources & References
16 official sources cited• CDC Vaccines and Immunizations: HPV Vaccination (2025)
• FDA HPV Vaccine Information, Merck Gardasil/Gardasil 9 Product Labels
• WHO statement on HPV vaccine safety, 2017
• Hviid A, et al. Association Between Human Papillomavirus Vaccination and Risk of Autoimmune Disease. NEJM. 2018;379:244-252
• Bruesewitz v. Wyeth, 562 U.S. 223 (2011) - Supreme Court Decision
• National Childhood Vaccine Injury Act (42 U.S.C. §300aa-11)
• VICP Vaccine Statistics, March 2024, Health Resources and Services Administration
• MDL-3036 Official Docket, W.D. North Carolina (JPML Transfer Aug 4, 2022)
• 770 F. Supp. 3d 893 - Bellwether Summary Judgment Opinion (2024)
• Gardasil Clinical Trial Data, FDA Approval Document (NDA 21-244)
• European Medicines Agency EMA/PRAC assessment of HPV vaccines
• American Academy of Pediatrics (AAP) HPV Vaccination Recommendations (2025)
• National Institutes of Health (NIH) HPV and Cancer Prevention
• WHO-SAGE on HPV vaccine safety monitoring (2017-2024)
• International Agency for Research on Cancer (IARC) - Cervical Cancer Prevention
• AboutLawsuits.com MDL-3036 Gardasil Litigation Updates
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.